A cura di Simona Lucchesi. UOSD Farmacologia Clinica. AOU “G. Martino” Messina
|
Principio attivo |
Effetto |
|
Atazanavir (1,2) |
Diminuzione della concentrazione/esposizione di atazanavir e/o aumento della concentrazione di tenofovir |
|
Darunavir (3) |
Aumento dell’esposizione a tenofovir |
|
Didanosina (4-12) |
Aumento delle concentrazioni plasmatiche di didanosina e rischio di tossicità da didanosina (neuropatia, diarrea, pancreatite, acidosi lattica severa) |
|
Lopinavir (13) |
Aumento della biodisponibilità di tenofovir |
|
Ritonavir (14) |
Aumento della biodisponibilità di tenofovir |
|
Tipranavir (15) |
Diminuzione delle concentrazioni plasmatiche di tipranavir |
Bibliografia
- Product Information: REYATAZ(R) oral capsules, atazanavir sulfate oral capsules. Bristol-Myers Squibb Company, Princeton, NJ, Feb, 2011.
- Product Information: VIREAD(R) oral tablets, tenofovir disoproxil fumarate oral tablets. Gilead Sciences, , Foster City, CA, Oct, 2010.
- Product Information: VIREAD(R) oral tablets, oral powder, tenofovir disoproxil fumarate oral tablets, oral powder. Gilead Sciences, Inc. (per FDA), Foster City, CA, Oct, 2013.
- Richard JN, et al. Pancreatitis with didanosine and tenofovir disoproxil fumarate (corrected). Clin Infect Dis 2003; 37: e57-62.
- Fulco P, Kirian M. Effect of tenofovir on didanosine absorption in patients with HIV. Ann Pharmacother 2003; 27: 1325-1328.
- Guo Y, Fung HB. Fatal lactic acidosis associated with coadministration of didanosine and tenofovir disoproxil fumarate. Pharmacotherapy 2004; 24: 1089-1094.
- Kearney BP, Damle B, Plummer A et al. Tenofovir DF (TDF) and didanosine EC (ddl EC): investigation of pharmacokinetic (PK) drug-drug and drug-food interactions. Sixth International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 2002, p 186, 2002.
- Kirian MA, et al. Acute onset of pancreatitis with concomitant use of tenofovir and didanosine. Ann Pharmacother 2004; 38: 1660-1663.
- Martinez E, et al. Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults. Lancet 2004; 364: 65-67.
- Murphy M, et al. Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine. Clin Infec Dis 2003; 36: 1082-1085.
- Negredo E, et al. Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. Aids 2004; 18: 459-463.
- S. Department of Health and Human Services: Guidelines for the use of antiretroviral agents in HIV-1-Infected adults and adolescents. U.S. Department of Health and Human Services, Washington, DC, Oct 14, 2011. Available at: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf’utm_source=AAG&utm_medium=E-mail&utm_campaign=Adult%2BGuidelines.
- Product Information: VIREAD(R) Oral Tablet , tenofovir disoproxil fumarate oral tablet. Gilead Sciences, Inc, Foster City, CA, May, 2005
- Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. AIDSinfo, Department of Health and Human Services, Rockville, MD, Apr 06, 2012. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf.
- Langmann P, et al. Low trough levels of tipranavir in a combination antiretroviral therapy of tipranavir/ritonavir and tenofovir require therapeutic drug monitoring. Eur J Med Res 2008; 13: 469-471.
Link